Huadong Medicine and Insilico Medicine announced that the companies have entered into a co-development partnership to accelerate the discovery of breakthrough small-molecule therapeutics by leveraging an innovative approach to oncology. Pursuant to the collaboration agreement, Insilico and Huadong Medicine will launch a new drug discovery project involving the research and development (R&D) teams of both parties. The collaboration will leverage Huadong Medicine's advanced innovative drug discovery and screening characterization platform, in combination with Insilico's end-to-end AI-driven drug discovery platform, particularly the small molecule generation platform Chemistry42, in order to design and screen out potential first-in-class drug molecules with superior activity that may increase the druggability of targets. The project team will interfere with protein-protein interactions to hit undruggable targets that regulate tumor growth. Insilico's self-developed small molecule generation platform Chemistry42 combines AI technology with computational and medicinal chemistry methods to efficiently generate novel molecular structures with desired properties for specific targets. This platform helps to screen and obtain potential therapeutic molecules, which are verified in vitro and in vivo, and delivers rapid comprehensive solutions from hits to preclinical candidates.